Department of Haematology, Derriford Hospital, Plymouth, UK.
Clin Med Insights Oncol. 2012;6:31-9. doi: 10.4137/CMO.S6637. Epub 2012 Jan 4.
Hodgkins' lymphoma (HL) which has relapsed post or is refractory to autologous bone marrow transplant presents an ongoing treatment challenge. Development of monoclonal antibodies (mAb) for the treatment of HL has aimed to replicate the success of mAb therapy in the treatment on Non Hodgkins Lymphoma. The identification of CD30 as a potential target for treatment has led to the development of a new antibody-drug conjugate, brentuximab vedotin (SGN-35), which conjugates monomethyl auristatin E to an anti-CD30 antibody to deliver targeted toxicity to the malignant Reed Sternberg cells of HL. This review describes CD30 as an antibody target, and focuses on the antibody-drug conjugate brentuximab vedotin, including current knowledge of the mechanism of action, preclinical, clinical and pharmacokinetic data available for Brentuximab Vedotin.
霍奇金淋巴瘤（HL）在自体骨髓移植后复发或难治，这是一个持续存在的治疗挑战。为了治疗 HL，开发了单克隆抗体（mAb），旨在复制 mAb 治疗非霍奇金淋巴瘤的成功。CD30 的鉴定作为治疗的潜在靶点，导致了一种新的抗体药物偶联物，brentuximab vedotin（SGN-35）的发展，它将单甲基澳瑞他汀 E 与抗 CD30 抗体结合，将靶向毒性传递给 HL 的恶性 Reed Sternberg 细胞。这篇综述描述了 CD30 作为一个抗体靶点，并重点介绍了抗体药物偶联物 brentuximab vedotin，包括其作用机制、临床前、临床和药代动力学数据的最新知识。
